Washington, DC being the capital of the US, perhaps may still be called the capital of the world. Full of monuments and memorials, eclectic neighborhoods, and true local flavor, all of these mingled with an ongoing quest for power, richness and global influence – surly DC is a place unlike any other. All major deals, agreements or disputes were made here or under the auspices of the locator of the White House. Thus, no wonder why the world’s leading cardiovascular professionals this year came together in Washington, DC for 3 full days of innovative education, ground-breaking science and interactive debates and discussion. The 66th American College of Cardiology (ACC) Congress was held at the Walter E. Washington Convention Centre between 17th till 19th March earlier this year.

And now a little about the numbers. This year’s meeting featured 23 Late-Breaking Clinical Trials (LBCTs) presentations, 17 Featured Clinical Research presentations, and 2572 abstracts were presented in oral and poster sessions by over 2000 experts. Further, over 300 education sessions were led by more than 1550 faculty members. The cornerstone of the meeting was “Meaningful Education at its Best” that became not only a slogan but an active engagement amongst the entire cardiovascular team. Apart from dedicated and highly sophisticated sessions, more global or public-oriented lectures, such as preventive initiatives under the umbrella of “Million Hearts,” “Barriers to New Medications for Cardiovascular Diseases” or “Emerging Trends in CV Medicine in 2107.” Additionally, professor Valentin Fuster, who is the Editor-in-Chief of the Journal of the American College of Cardiology (JACC) announced that JACC was once again ranked #1 among 124 CV journals worldwide, according to the 2015 Impact Factor. Moreover, JACC: Cardiovascular Imaging and JACC: Heart Failure, with their IF exceeding 7.0, were also ranked among the top 10 CV journals.

Without doubt, it is impossible to present the full coverage of the ACC Congress in the short summary. However, there are some important issues for entire cardiology community, that need to be addressed. Firstly, there were several LBCTs that will surely change the landscape of the today’s cardiology. Professor Marc Sabatine gave results of the highly anticipated FOURIER trial. He announced that addition of evolocumab, a PCSK9 inhibitor, to statin therapy over several years significantly reduced CV morbidity and mortality in patients with clinically evident atherosclerotic CV disease. Remarkably, evolocumab was able to reduce LDL-C by 59% from a median 92 to 30 mg/dl. Importantly, this reduction was maintained throughout the duration of the study. The good news is that at last we have a real game-changing new drug that shows promise for the future. According to the SURTAVI trial, transcatheter aortic valve replacement (TAVAR) was found to be non-inferior to surgical aortic valve replacement (SAVR) in patients with symptomatic, severe aortic stenosis who had an intermediate level of operative risk. In the SURTAVI trial self-expanding CoreValve and the new Evolut-R valves, were used in 84 and 16% of TAVR patients, respectively. The trial’s main conclusion was that TAVR was just as good as surgery, but it was not superior to it. Further, long awaited DECISION-CTO randomized clinical trial comparing a strategy of percutaneous revascularization in chronic total occlusions (CTO) vs. optimal medical treatment (OMT) was presented. Surprisingly for some, however, anticipated by others the trial failed to show any significant difference in the primary composite endpoint (mortality of any cause, non-fatal myocardial infarction [MI] and any revascularisation) at 3-years follow-up. There were numerous issues raised by the layout of the trial, nevertheless, we have at last strong piece of evidence that PCI of the CTO is not an automatic and default procedure for everyone and sometimes it is wise to take a step back rather than spend six hours in the cath-lab. There were also several studies from the heart failure (HF) field that warrants further attention. Doctor Parham Zarrini presented the newest ancillary findings within the WISE population who studied patients with HF and preserved ejection fraction (HFrEF) and persistent pro-inflammatory state as measured by interleukin-6 (IL-6). The authors
found that a chronic pro-inflammatory state leads to endothelial and non-endothelial microvascular dysfunction, which has been shown to be associated with HFrEF. Additionally, doctor Allen J. Weiss reported that T1-mapping during cardiac magnetic resonance (CMR) imaging detects interstitial myocardial fibrosis (IMF) and that patients with HFrEF had more IMF than healthy controls. Is this likely that the increase in IMF contributes to impaired diastolic function and HF severity in HFrEF? They concluded that T1 mapping appears to be a promising tool for evaluating patients with HFrEF. Finally, it was revealed that Levosimendan does not meet primary endpoint in the LEVO-CTS trial. Although the clinical benefit was gained with the calcium-sensitizing inotrope levosimendan, the co-primary endpoints were not significantly improved in the LEVO-CTS trial evaluating the effect of the drug to prevent low cardiac output syndrome and its associated adverse outcomes in patients with a low LVEF undergoing cardiac surgery. The authors concluded that despite the fact that the drug had its intended biologic effect in increasing cardiac output and reducing low cardiac output syndrome, that did not translate into a reduction in our endpoints.

Lastly, it should be mentioned about our own input into the congress's scientific content. Doctor Pawel Rubis presented two abstracts, entitled "Relations Between Fibrosis-linked Micrornas (mir-21, Mir-26, Mir-29, Mir-30 And Mir-133a) And Right Ventricular Morphology And Function In Dilated Cardiomyopathy" and "Associations Between Serum Markers Of Extracellular Matrix Metabolism, Fibrosis-linked Micrornas (mir-21, Mir-26, Mir-29, Mir-30 And Mir-133a) And Right Ventricular Parameters In Dilated Cardiomyopathy" during the session: Cardiac Fibrosis and Heart Failure: The Next Frontier. The presentations raised several comments from the audience and few hopefully fruitful ideas were exchanged.
**Information for authors**

**Aims and scope**
Journal of Rare Cardiovascular Diseases (JRCD) is an international, quarterly, peer reviewed journal that keeps cardiologists up to date with rare disorders of heart and vessels. Topics covered include congenital heart defects, cardiomyopathies, rhythm abnormalities, rare forms of arterial hypertension, pulmonary hypertension, cardiac tumors and other rare diseases affecting heart and vessels such as connective tissue diseases, metabolic disorders, neuro-muscular diseases another unclassified rare diseases.

**Instructions for authors**
The Journal will consider for publication articles written in English.

**Types of papers**
The following types of papers will be considered for publication in JRCD:
- Original articles: word limit 4000 words, 40 references, no more than 6 figures/tables
- Review articles: word limit 5000 words, 50 references, no more than 5 figures
- Brief Report: word limit 2000 words, 20 references, no more than 4 figures
- Case Report: word limit 3500 words, 30 references, no more than 5 figures.

**Letter to editor:** up to 600 words

**Editorial**
The type of paper should be indicated on the title page.

**Manuscript submission**
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

**Permissions**
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

**Online Submission**
All articles must be submitted using an electronic submission system at: [www.jrcd.eu](http://www.jrcd.eu).

**Title page**
The title page should include:
- Type of paper
- The name(s) of the author(s)
- A concise and informative title
- The affiliation(s) and address(es) of the author(s)
- The e-mail address, telephone and fax numbers of the corresponding author
- Declaration of conflict of interest

**Abstract**
Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.

**Keywords**
Please provide 4 to 6 keywords which can be used for indexing purposes.

**Text**
**Text Formatting**
Manuscripts should be submitted in Word.
- Use a normal, plain font (e.g., 12-point Times Roman) for text.
- Use italics for emphasis.
- Use the automatic page numbering function to number the pages.
- Do not use field functions.
- Use tab stops or other commands for indents, not the space bar.
- Use the table function, not spreadsheets, to make tables.
- Use the equation editor or MathType for equations.
- Save your file in doc format. Do not submit docx files.

**Headings**
Please use no more than three levels of displayed headings.
- Original article should consists of the following sections:
  - Background
  - Methods
  - Results
  - Discussion
  - Conclusions
  - References
- Case reports should include the following headings:
  - Case presentation
  - Review of literature
  - Patient management and follow-up
  - References

**Abbreviations**
Abbreviations should be defined at first mention and used consistently thereafter.

**Footnotes**
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
- Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data).
- Footnotes to the title or the authors of the article are not given reference symbols.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full.

Scientific style Please always use internationally accepted signs and symbols for units (SI units).
Generic names of drugs are preferred; if trade names are used, the generic name should be given at first mention.

References
Reference citations in the text should be identified by numbers in square brackets [].

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.

The entries in the list should be numbered consecutively.
The example:
Please, list the first three authors and add “et al.”.

Tables
All tables are to be numbered using Arabic numerals.
Tables should always be cited in text in consecutive numerical order.
For each table, please supply a table caption (title) explaining the components of the table.
Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
Footnotes to tables should be indicated by superscript lower-case letters and included beneath the table body.

Artwork / Figure
For the best quality final product, it is highly recommended that you submit all of your artwork – photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest standards with the greatest accuracy to detail. The published work will directly reflect the quality of the artwork provided.
Supply all figures electronically.
Indicate what graphics program was used to create the artwork.

Figure Numbering
All figures are to be numbered using Arabic numerals.
Figures should always be cited in text in consecutive numerical order.
Figure parts should be denoted by lowercase letters (a, b, c, etc.). Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Permissions
If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Publisher will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Electronic Supplementary Material
We accept electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online. This feature can add dimension to the author’s article.
Supply all supplementary material in standard file formats. Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.
For each supplementary material, please supply a concise caption describing the content of the file.

Ethical standards
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements.

Conflicts of interest
Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research. They should also state that they have full control of all primary data and that they agree to allow the journal to review their data if requested.
Therefore the manuscript must be accompanied by the “Conflict of Interest Disclosure Form”. To download this form, please follow the hyperlink on the right.

Copyright Transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.

Disclaimer
The authors, editors, and publisher will not accept any legal responsibility for any errors or omissions that may be made in this publication.
The publisher makes no warranty, express or implied, with respect to the material contained herein.